Skip to main content
. 2020 Jan 27;10:3087. doi: 10.3389/fimmu.2019.03087

Figure 1.

Figure 1

Comparison of miR-221-3p and miR-155-5p expression levels in clinical samples from healthy donors (HD), patients with rheumatoid arthritis (RA), other inflammatory arthritis (OIA) and osteoarthritis (OA). (A) miR expression levels in the synovial fluid of RA patients were compared to patients with OIA (psoriatic- and spondyloarthritis) and OA, and miR expression in synovial tissue was compared between biopsy samples from RA and OA patients. (B) miR expression levels were measured in plasma, PBMCs and isolated CD14+ cells from the peripheral blood of RA patients and HD. miR expression was measured by qRT-PCR and normalized to control miRs (miR-16-5p, miR-103-5p, miR-15b-5p, or spike-in cel-miR-39) and expressed as 2−ΔCT by boxplot with min/max whiskers. N = 4–6, *p < 0.05. (C) −ΔCT level of miR-221-3p was plotted against miR-155-5p level from synovial fluid, tissue and CD14+ cells from blood and the Pearson or Spearman correlation and p-values were computed. Data are plotted with regression coefficients (solid line) and 95% confidence intervals (broken lines). (D) Expression levels of tested miRs were compared in M1- and M2-macrophages generated from CD14+ cells of PBMCs from HD or RA patients and presented as 2−ΔCT by boxplot with min/max whiskers. N = 3–6, *p < 0.05.